NEW ORLEANS — In low-risk patients with atrial fibrillation for whom anticoagulation therapy would be indicated, device-based left atrial appendage closure (LAAC) was about equal to non-vitamin K antagonist oral anticoagulant (NOAC) therapy in preventing serious cardiovascular events. However, whether the procedure is an alternative for NOAC therapy to reduce stroke risk is an open question.
LAAC ...
The CHAMPION-AF trial presents a compelling case for LAAC as a noninferior alternative to NOACs in low-risk AF patients, particularly in reducing bleeding risks. The study’s rigorous design and large sample size lend credibility to its findings, and the net clinical benefit analysis suggests LAAC may offer advantages beyond stroke prevention alone. However, the trial’s exclusion of high-risk patients and lack of a control group raise valid concerns about generalizability. The conflicting results...